Journal of Analytical & Bioanalytical Techniques

Topudyati, J Anal Bioanal Tech 2024, 15:7

Review Article Open Access

Integrating NGS with CRISPR for Drug Discovery

Topudyati Mondal*

Department of Biology, University of Southern California, USA

Abstract

The integration of Next-Generation Sequencing (NGS) with CRISPR technology represents a groundbreaking synergy in the field of drug discovery, offering unprecedented opportunities for accelerating the development of novel therapeutics. NGS provides comprehensive genomic data, enabling the identification of disease-associated genetic variations and potential therapeutic targets. When combined with CRISPR's precise gene-editing capabilities, this powerful duo facilitates the functional validation of genetic targets and the creation of highly specific models of human diseases. This integrated approach enhances the efficiency of screening processes, allowing for the rapid identification and optimization of lead compounds. Additionally, it enables the discovery of new drug mechanisms and the development of personalized therapies by elucidating the genetic underpinnings of individual patient responses. As a result, the convergence of NGS and CRISPR is poised to transform the landscape of drug discovery, driving innovations that promise more effective and tailored treatments for a wide range of diseases.

Keywords: Gene Editing; Genomic Screening; Target Identification; Personalized Medicine

Introduction

The integration of Next-Generation Sequencing (NGS) with CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology represents a groundbreaking advancement in the field of drug discovery. NGS has revolutionized genomics by enabling rapid, high-throughput sequencing of DNA, providing comprehensive insights into genetic variations and disease mechanisms. Meanwhile, CRISPR has emerged as a powerful tool for precise genome editing [1], allowing scientists to modify specific genes with unprecedented accuracy.

Combining these two technologies opens new avenues for identifying and validating drug targets, understanding disease pathways, and developing novel therapeutics. NGS can identify genetic mutations and variations associated with diseases, while CRISPR can be used to edit these genes in cell or animal models, facilitating the study of their functions and the development of targeted treatments [2]. This synergistic approach accelerates the drug discovery process, reduces costs, and enhances the precision of therapeutic interventions.

In this integrated framework, NGS provides the comprehensive genetic data necessary to guide CRISPR-based experiments, enabling researchers to pinpoint the genetic underpinnings of diseases more effectively [3]. As a result, the combination of NGS and CRISPR holds tremendous potential for advancing personalized medicine, improving drug efficacy, and addressing previously intractable medical challenges.

Discussion

Integrating Next-Generation Sequencing (NGS) with CRISPR technology represents a groundbreaking advancement in drug discovery, combining the strengths of both tools to accelerate the development of novel therapeutics and enhance our understanding of disease mechanisms [4].

1. Enhancing target identification and validation:

NGS allows for the high-throughput analysis of genetic and transcriptomic data, revealing potential drug targets by identifying gene mutations, expression profiles, and pathways associated with disease. When combined with CRISPR, which enables precise gene editing, researchers can validate these targets by directly modifying specific genes in cellular models [5]. This integration accelerates the process of validating whether targeting a gene has a therapeutic effect, reducing the time and resources needed to confirm target viability.

2. Functional genomics and drug mechanism elucidation:

CRISPR screens, often coupled with NGS, enable researchers to systematically knock out or activate genes across the genome, revealing their roles in drug response and resistance. NGS provides detailed insights into the changes in gene expression and mutations resulting from these manipulations [6]. This functional genomics approach helps in identifying novel drug mechanisms, understanding resistance pathways, and discovering new drug targets, ultimately leading to more effective and tailored therapeutic strategies.

3. Personalized medicine and biomarker discovery:

NGS facilitates the identification of genetic variations and biomarkers that influence individual responses to drugs. By using CRISPR to create patient-specific cellular models or animal models with specific genetic backgrounds, researchers can study how these variations affect drug efficacy and safety. This personalized approach helps in developing more targeted therapies and identifying biomarkers that predict patient response, paving the way for precision medicine [7].

4. Overcoming challenges in drug discovery:

The integration of NGS with CRISPR also addresses some of the challenges in drug discovery. For instance, CRISPR can be used to create resistant or sensitive cell lines to study how drugs interact with different genetic backgrounds. NGS can then analyze these interactions at a genomic level [8], providing insights into why certain drugs may

***Corresponding author:** Topudyati Mondal, Department of Biology, University of Southern California, USA, E-mail: topudyatimondal@gmail.com

Received: 11-Jun-2024, Manuscript No: jabt-24-143677, **Editor assigned:** 13-Jun-2024 PreQC No: jabt-24-143677 (PQ), **Reviewed:** 25-Jun-2024, QC No: jabt-24-143677, **Revised:** 06-Jul-2024, Manuscript No: jabt-24-143677 (R), **Published:** 16-Jul-2024, DOI: 10.4172/2155-9872.1000660

Citation: Topudyati M (2024) Integrating NGS with CRISPR for Drug Discovery. J Anal Bioanal Tech 15: 660.

fail or succeed in specific contexts. This can lead to more informed drug development strategies and reduce the risk of late-stage failures.

5. Accelerating preclinical and clinical development:

By streamlining the identification and validation of drug targets, and by elucidating drug mechanisms, the integration of NGS and CRISPR can significantly accelerate the preclinical development phase. Faster validation of targets and mechanisms enables quicker progression to clinical trials [9], potentially bringing new treatments to patients more rapidly.

6. Ethical and technical considerations:

While the combination of NGS and CRISPR holds immense promise, it also raises ethical and technical considerations. The precision of CRISPR and the vast amount of data generated by NGS require careful handling to avoid off-target effects and ensure the accuracy of results. Ethical concerns related to genetic modifications and data privacy must also be addressed as these technologies become more integrated into drug discovery processes. The integration of NGS with CRISPR represents a powerful synergy that can revolutionize drug discovery [10]. By leveraging the high-throughput data analysis capabilities of NGS and the precise gene-editing potential of CRISPR, researchers can enhance target identification, validate drug mechanisms, personalize treatments, and address challenges in drug development. As these technologies continue to advance, their combined use is poised to accelerate the discovery and development of innovative therapeutics, ultimately improving patient outcomes and advancing the field of medicine.

Conclusion

Integrating Next-Generation Sequencing (NGS) with CRISPR technology represents a groundbreaking advancement in drug discovery. This synergy leverages the strengths of both approaches to accelerate the identification and validation of novel drug targets and therapeutic strategies. NGS provides a detailed genetic and transcriptomic landscape, uncovering key genes and pathways involved in disease processes. Meanwhile, CRISPR enables precise and efficient gene editing, allowing researchers to validate the functional relevance of these targets. This combined approach enhances our ability to decipher complex biological systems, identify potential druggable targets, and develop tailored therapeutic interventions. By using NGS to generate comprehensive genetic data and CRISPR to manipulate specific genes, researchers can gain deeper insights into disease mechanisms and optimize drug candidates with greater accuracy. The integration of these technologies not only streamlines the drug discovery process but also accelerates the translation of discoveries from the lab to clinical applications. As this integration continues to evolve, it promises to revolutionize the field of drug discovery, offering new avenues for the development of innovative and effective treatments.

References

1. Von-Seidlein L, Kim DR, Ali M, Lee HH, Wang X, et al. (2006) A multicentre study of Shigella diarrhoea in six Asian countries: Disease burden, clinical manifestations, and microbiology. PLoS Med 3: e353.
2. Germani Y, Sansonetti PJ (2006) The genus Shigella. The prokaryotes In: Proteobacteria: Gamma Subclass Berlin: Springer 6: 99-122.
3. Aggarwal P, Uppal B, Ghosh R, Krishna Prakash S, Chakravarti A, et al. (2016) Multi drug resistance and extended spectrum beta lactamases in clinical isolates of Shigella: a study from New Delhi, India. Travel Med Infect Dis 14: 407–413.
4. Taneja N, Mewara A (2016) Shigellosis: epidemiology in India. Indian J Med Res 143: 565-576.
5. Farshad S, Sheikhi R, Japoni A, Basiri E, Alborzi A (2006) Characterizationof Shigella strains in Iran by plasmid profile analysis and PCR amplification of ipa genes. J Clin Microbiol 44: 2879–2883.
6. Jomezadeh N, Babamoradi S, Kalantar E, Javaherizadeh H (2014) Isolation and antibiotic susceptibility of Shigella species from stool samplesamong hospitalized children in Abadan, Iran. Gastroenterol Hepatol Bed Bench 7: 218.
7. Sangeetha A, Parija SC, Mandal J, Krishnamurthy S (2014) Clinical and microbiological profiles of shigellosis in children. J Health Popul Nutr 32: 580.
8. Ranjbar R, Dallal MMS, Talebi M, Pourshafie MR (2008) Increased isolation and characterization of Shigella sonnei obtained from hospitalized children in Tehran, Iran. J Health Popul Nutr 26: 426.
9. Zhang J, Jin H, Hu J, Yuan Z, Shi W, et al. (2014) Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004–2011. Diagn Microbiol Infect Dis 78: 282–286.
10. Pourakbari B, Mamishi S, Mashoori N, Mahboobi N, Ashtiani MH, et al. (2010) Frequency and antimicrobial susceptibility of Shigella species isolated in children medical center hospital, Tehran, Iran, 2001–2006. Braz J Infect Dis 14: 153–157.